Research programme: peripheral NMDA receptor antagonists - Rottapharm

Drug Profile

Research programme: peripheral NMDA receptor antagonists - Rottapharm

Alternative Names: CR 3663

Latest Information Update: 23 Oct 2014

Price : $50

At a glance

  • Originator Rottapharm Madaus
  • Class Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Osteoarthritis

Most Recent Events

  • 23 Oct 2014 Early research is ongoing in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
  • 24 Feb 2010 Early research in Osteoarthritis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top